

October 29, 2015

**The Dy. General Manager
Dept. of Corporate Affairs
The Bombay Stock Exchange Ltd,
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai: 400001**

Dear Sir,

We refer to your letter L/DOSS/ONL/RV/RD/2015-16/143 subject to Clarification/Confirmation on news item appearing "CNBC TV 18" dated October 29, 2015.

Please note that as a part of the Management Discussion and Analysis Report on the Unaudited Financial Results for the quarter/half year ended September 30, 2015 announced to the stock exchange today, the Company has disclosed the following information on the said molecule as under:

"Sanofi has made the decision not to pursue further Vatelizumab as a potential Relapsing-Remitting MS therapy, following the results of a pre-planned interim analysis that revealed the primary efficacy endpoint was not met. This decision is not due to safety concerns. Glenmark will continue to pursue the relicensing of Vatelizumab after it's returned from Sanofi."

Thanking you.

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.



**Sanjay Kumar Chowdhary
Company Secretary & Compliance Officer**

Tel: 4018 9999 / 4018 9879
Fax No: 4018 9986 (Legal & Secretarial Dept.)

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099.

T: 91 22 4018 9999 F: 91 22 4018 9988 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026

CIN No: L24299MH1977PLC019982 E: complianceofficer@glenmarkpharma.com